DJPL to invest Rs. 4.7 billion in Chitwan

Kathmandu, Feb. 4

Deurali-Janta Pharmaceuticals Pvt. Ltd. is set to diversify its production and increase its capacity with a new manufacturing plant in Chitwan.

“The new international standard production plant will be installed for Rs 4.75 billion, with the aim of import substitution, export readiness, technology transfer and creating employment,” Hari Bhakta Sharma, Founder and Executive Director of the company, said at a  press meet organised to mark the 35^th year of the company, on Tuesday.

The project would be developed within two years.

Sharma and his team have seen a huge potential in the Nepali pharmaceutical industry in production, export and competitive capacity.

However, he said that the country still lacks an industry-friendly policy. The government should support the entrepreneurs in acquiring land, the business registration and licensing process, and technology transfer.

According to him, the Department of Drugs has a provision for obtaining a separate license for each medicine production, which creates additional hassles in the production and marketing of the products.

Deurali-Janta aims to conduct a business worth around Rs. 2.6 billion this year.

“Deurali–Janata Pharmaceuticals has been a leader in Nepal’s pharmaceutical industry for the past 35 years. The company imports advanced technology to produce essential medicines locally, and it has firmly established itself as a pioneer in Nepal’s pharmaceutical sector,” said Ayush Bhakta Poudel, Director of the company.

According to him, with a focus on reducing reliance on imported medicines, the company’s goal has always been to make the country self-sufficient in pharmaceutical production. It has successfully developed and produced hundreds of medicines in Nepal, and the company’s success story is a testament to its commitment and growth in the pharmaceutical industry.

Deurali-Janta is producing 296 types of essential life-saving medicines, including capsules, tablets, liquids, ointments, dry powders, and other forms of medicinewith the application of cutting-edge technologies.

The products are rigorously researched, produced, and quality-tested using modern technologies and equipment, meeting international standards, said Poudel. The company has employed 675 individuals. 

Published in The Rising Nepal daily on 5 February 2026.